Hyoscine butylbromide, Analgesics, Non-Narcotic — Competitive Intelligence Brief

Hyoscine butylbromide, Analgesics, Non-Narcotic (Hyoscine butylbromide, Analgesics, Non-Narcotic) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic antispasmodic. Area: Gastroenterology.

phase 3 Anticholinergic antispasmodic Muscarinic acetylcholine receptors Gastroenterology Small molecule

Target snapshot

Hyoscine butylbromide, Analgesics, Non-Narcotic (Hyoscine butylbromide, Analgesics, Non-Narcotic) — London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Hyoscine butylbromide is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce smooth muscle spasms and secretions.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hyoscine butylbromide, Analgesics, Non-Narcotic TARGET	Hyoscine butylbromide, Analgesics, Non-Narcotic	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	phase 3	Anticholinergic antispasmodic	Muscarinic acetylcholine receptors
SCOPOLAMINE	SCOPOLAMINE		marketed	Anticholinergic [EPC]	Muscarinic acetylcholine receptors	1979-01-01
Enlon-Plus	Atropine Sulfate	Alcon Labs Inc	marketed	Antimuscarinic agent	Muscarinic acetylcholine receptors	1960-01-01
Neostigmine + Atropine	Neostigmine + Atropine	China Medical University Hospital	marketed	Cholinesterase inhibitor + Anticholinergic agent	Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (atropine)
neostigmine/glycopyrolate	neostigmine/glycopyrolate	Henry Ford Health System	marketed	Cholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrolate)
ACs	ACs	GlaxoSmithKline	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (non-selective or subtype-specific)
Neostigmine with glycopyrrolate	Neostigmine with glycopyrrolate	The Cleveland Clinic	marketed	Acetylcholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase; muscarinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic antispasmodic class)

1. Chong Kun Dang Pharmaceutical · 1 drug in this class
2. London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · 1 drug in this class
3. Sisli Hamidiye Etfal Training and Research Hospital · 1 drug in this class